Baby Bunting Group (ASX:BBN) Chief Executive Mark Teperson has been diagnosed with myelofibrosis, a rare form of bone marrow cancer, though his condition is low-risk and expected to progress slowly, according to a Monday Australian bourse filing.
Teperson remains committed to leading the company's growth, with his non-invasive treatment not affecting his CEO duties, the filing added.
The company's shares fell around 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.